4D Pharma Clinical Update - MRx0518 Oncology Programmes

- Update on MRx0518 Phase I/II combination study with KEYTRUDA® (pembrolizumab)

The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc...

from Today http://bit.ly/2Wfi9f2
via IFTTT